P
ostmastectomy radiation therapy for patients affected by locally advanced breast cancer is a mandatory part of a multimodality treatment involving upfront chemotherapy and mastectomy. 1 Postmastectomy radiotherapy has also been demonstrated to increase both local control and survival in women preoperatively diagnosed with early-stage breast cancer that on permanent histologic assessment revealed extensive nodal involvement. 2, 3 This condition is not entirely predictable before mastectomy; therefore, the reconstructive and therapeutic procedures may interfere, thus creating treatment delays or increasing the complication rate.
A rational choice for patients whose indication for postmastectomy radiotherapy is preoperatively known would suggest delaying the reconstruction until after the completion of irradiation; a subsequent flap-based operation with removal of radiation-injured skin would provide fresh autologous tissue and lead to optimal results. However, not all patients are in favor of postponing breast reconstruction until after the irradiation or willing to undergo complex flap-based operations.
In some cases, radiotherapy could be indicated after placement of a temporary expander as the first stage of a two-stage procedure. Several studies [4] [5] [6] have demonstrated the conflicting coexistence of implants in the setting of irradiated tissues, with a severe increase in the complication rate.
Two populations were investigated in this work: the first population (group 1) was made up of women affected by early-stage breast cancer with extensive nodal involvement that required postmastectomy radiotherapy and adjuvant chemotherapy; a second population (group 2) was made up of patients with locally advanced breast cancer who preoperatively were candidates for radiotherapy and who received chemotherapy before surgery. We used these two populations as a field for observation of two different timings of radiotherapy administration: in group 1 on permanent implants (radiotherapy plus permanent implants), and in group 2 during the expansion phase (radiotherapy plus tissue expanders). A third population who did not receive radiotherapy was included as a control group.
The estimate of the totally failed reconstruction rate was the principal endpoint of this study. Capsular contracture rates and patients' and surgeons' subjective evaluations were the secondary endpoints.
PATIENTS AND METHODS
From October of 2003 to October of 2007, a total of 257 patients (mean age, 49 years) were prospectively involved in this study. The population was stratified as follows: group 1, radiotherapy on permanent implants (n ϭ 109 patients); and group 2, radiotherapy on tissue expanders (n ϭ 50 patients). A third group (control group) made up of 98 patients was selected randomly among the overall non-radiotherapy-treated population during the study span. All patients underwent a twostage immediate breast reconstruction with subpectoral temporary expanders (ST 133; Allergan, Inc., Irvine, Calif.) and permanent implants (ST 410-510; Allergan). The timing of radiotherapy for group 1 was planned as described in Figure 1 . Patients with locally advanced breast cancer were preoperatively scheduled for radiotherapy as described in Figure 2 .
The three subgroups were matched for possible risk factors for complications. No significant differences in the incidence of smoking (p ϭ 0.7) or diabetes (p ϭ 0.4) were evident in the three subgroups. The treatment timing was selected in accordance with institutional, national, and international guidelines on breast cancer treatment. 7, 8 All patients were followed up for a median of 50 months.
Irradiation was delivered to the permanent implant or on the temporary expander (once completely expanded) with cobalt-60 or 6-MV tangent photon beams using three-dimensional conformal radiotherapy; techniques do not differ from standard treatment after breast-conservation surgery. Volumes included the chest wall with the implant and the supraclavicular region. The prescribed dose was 50 Gy in 25 or 28 fractions; all fields were treated daily.
The primary endpoint of this study was to assess the total failure rate; the reconstruction was considered totally failed when the implant had to be removed, leaving the chest wall flat, or when change to a flap-based technique was required. The device could be removed for exposure or infection, poor results (e.g., severe asymmetry, distortion), or severe capsular contracture (i.e., Baker grade IV).
A secondary endpoint of the study was the assessment of the capsular contracture rates. The four-grade Baker scale was used for this purpose.
Patients' and surgeons' subjective evaluations were part of the secondary endpoint. Shape and symmetry were assessed by surgeons during outpatient consultation using three scores (good, medium, or bad). In the same way, patients were asked to rate their reconstruction as good, medium, or bad. All data were collected prospectively by a centralized database at our unit at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan. Statistical comparisons were made using the chisquare and Fisher's exact test. Values of p Ͻ 0.05 were considered statistically significant.
RESULTS
The totally failed reconstruction rate was significantly higher in group 2, with 40 percent of unsuccessful reconstructions, compared with 6.4 percent in group 1 and 2.3 percent in the control group (p Ͻ 0.0001). In group 1, we observed seven cases of failed reconstruction: there was a severe capsular contracture in five cases, wound dehiscence in one case, and an infection that required implant removal in one case. The failed reconstructions in group 2 included either those stopped at the first stage with removal of temporary expander for extrusion or infection (10 of 20; extrusion with wound diastasis in five cases and infection and extrusion in five cases), or those converted to flap surgery after the second surgical stage because of extrusion (two cases), infection (three cases), or poor results (e.g., asymmetry, Baker grade IV capsular contracture) (five cases). We also calculated the relative risk for the two groups in comparison with the control group (19.6 in the tissue expander group and 3.1 in the permanent implant group) (Figs. 3 through 6).
The capsular contracture rate was significantly higher for groups 1 and 2 compared with the control group. The incidence of Baker grade IV capsular contracture was the highest in group 2 (13.3 percent, versus 10.1 percent in group 1 and 0 percent in the control group, p ϭ 0.0001) (Fig. 2) .
The shape assessment performed by the surgeons demonstrated a higher incidence of good results in group 1, although the highest value was still reported in the control group (group 1, 58.7 percent; group 2, 30.8 percent; control group, 74.2 percent; p ϭ 0.0009) ( Tables 1 through 3) .
The visual evaluation of symmetry revealed better results in group 1 in comparison with group 2. However, a prevalence of best results was still observed in the control group (p ϭ 0.01) ( Table 4) .
The estimate of patients' opinions demonstrated a higher prevalence of good results in group 1 in comparison with group 2. As mentioned previously, the best results are reported in the control group (good opinion: group 1, 52.2 percent; group 2, 46.2 percent; and control group, 68.1 percent; p ϭ 0.04) ( Table 5 ).
DISCUSSION
The modern oncologic/plastic surgical workflow in breast cancer surgery requires a full integration of therapeutic and reconstructive procedures. This is particularly true for patients at high risk scheduled to undergo complex multimodality treatments. 
Timing of Postmastectomy Radiotherapy and Chemotherapy
The adequate timing of adjuvant radiotherapy in breast cancer has become a subject of increasing interest in recent years. The results of an overview of trials of postmastectomy radiotherapy in patients who received chemotherapy, with a median follow-up of at least 5 years, indicated a benefit in mortality if the therapy had started within 6 months from surgery. 9 However, data regarding a delay of more than 6 months in starting postmastectomy radiation therapy when longer chemotherapy programs were given are controversial: some retrospective studies have not reported an adverse effect on outcome for locoregional recurrence at 8 years, 10 whereas a further study showed a higher local failure rate. 11 Relying on such considerations, 12 Kurtz et al. studied the impact of delaying radiotherapy and sequencing of radiotherapy and chemotherapy to optimize the therapeutic benefit from radiotherapy. They concluded that patients taking adjuvant chemotherapy should start radiotherapy within 4 weeks after the last cycle. The interval between chemotherapy and radiotherapy has also been evaluated by Wright et al., 13 who reported that a median 8-week interval from chemotherapy to irradiation allows excellent control rates for local and regional control, distant metastasis-free survival, and overall survival at 5 years.
In view of such evidence, we decided not to delay radiotherapy for more than 6 weeks from the RT, radiotherapy; PI, permanent implants; TE, tissue expanders. *Group 1 (radiotherapy on permanent implants) demonstrated a higher incidence of good rates in comparison with group 2. The highest incidence of good results is reported in the control group (p ϭ 0.01). Volume 128, Number 2 • Postmastectomy Radiation Therapy end of chemotherapy. During this time, we had a chance to perform the final reconstructive step (3 weeks after the last dose) and to start radiotherapy 3 weeks later.
Outcomes of Breast Reconstruction with Implants Followed by Postmastectomy Radiotherapy
Proper therapeutic timing is expected not to interfere with the reconstructive outcome of the procedure. Several studies reported a severe complication rate when radiotherapy was administered in two-stage breast reconstructions.
Krueger et al. 4 demonstrated on a short series that irradiated patients had a higher incidence of failures and complications for expander/implant reconstructions than nonirradiated patients. The observed failure rates were 37 percent (seven of 19) and 8 percent (five of 62) for patients treated with and without radiotherapy, respectively.
A series by Cordeiro et al. 14 evaluated the outcome of radiotherapy after the second stage on permanent prostheses. A significantly higher capsular contracture rate was demonstrated in radiotherapy patients: grade III, 23 (33.8 percent) with radiotherapy and seven (9.3 percent) without radiotherapy; and grade IV, four (5.9 percent) with radiotherapy and one (1.3 percent) without radiotherapy (p ϭ 0.0006). No statistically significant differences were evident between the two groups in the evaluation of cosmetic scores.
Anderson et al. 15 have recently reported major complications in a group of 62 patients with irradiation on tissue expanders that were compared with a group of 12 patients after irradiation on permanent implants: no significant differences were evident between the two groups (4.8 percent in the tissue expander group versus 0 percent in the permanent implant group). The small size of the sample may have affected the statistical power of the study.
This observation has now been contradicted by our work. Our cohort study was based on a larger population subdivided into three subgroups including a control group of nonirradiated patients. This design has allowed us to reach a higher level of evidence and an increased statistical strength. Randomized assignment of patients to each cohort was not possible because of the intrinsic characteristic of this study. In fact, we did not admit women affected by disease at the same stage to each treatment arm; we rather preferred to analyze the effects of radiotherapy delivered either on permanent implants (group 1) or during the expansion phase (group 2) on the reconstructive outcome.
In the first population, we took advantage of the chemotherapy interval to perform tissue expansion, deferring radiotherapy until shortly after the replacement with permanent implants. In the second cohort, we were forced by stage of disease to perform radiotherapy immediately after mastectomy. This may have generated some bias that could have been eliminated by a randomized trial analyzing different timings of two-stage reconstructions and adjuvant irradiation or chemotherapy in patients at the same stage.
Thus, in this study, the highest total failure rate is demonstrated in patients who underwent radiotherapy during the expansion phase (group 2). A slight increase is evident for group 1 (radiation after the second stage) in comparison with the control group (40 percent in group 2, versus 6.4 percent in group 1, versus 2.3 percent in the control group; p Ͻ 0.0001).
Similarly, the highest incidence of severe capsular contracture (Baker grade IV) is estimated for group 2; even in this case, the best results are shown in the nonirradiated cohort. However, narrow differences were observed between the two groups and the control group. This can be justified, hypothesizing that the very limited number of surviving reconstructions in group 2 will behave similarly to that of group 1 and of the control group.
A subjective evaluation of outcome demonstrated the best results in patients who had not undergone radiotherapy. The highest incidence of good results was significantly reported in the cohort who underwent radiotherapy on permanent implants, although even in this case, narrow differences were displayed between groups 1 and 2. Similar observations are reported for surgeons' evaluation of shape and symmetry.
CONCLUSIONS
This study demonstrated that a higher total failure rate affects breast reconstructions that undergo irradiation during tissue expansion. For this reason, we suggest that if tissue expansion can be performed during postoperative chemotherapy, chest wall irradiation should be delivered on permanent implants. The second surgical step can be scheduled 3 weeks after the end of chemotherapy, and the irradiation should not begin more than 3 weeks later. Patients whose need for radiotherapy is not known preoperatively can, in this way, improve their surgical outcome.
Future developments in this field will involve new technologies of regenerative medicine. The use of lipoaspirates as a therapeutic agent to treat radiation-induced damage of soft tissue is currently under investigation in our unit to allow immediate radiotherapy on temporary expanders in patients who received neoadjuvant chemotherapy. 
